2026-08-21 カリフォルニア大学リバーサイド校（UCR）
＜関連情報＞
- https://news.ucr.edu/articles/2026/08/21/study-suggests-new-antibody-therapy-tick-borne-disease
- https://www.nature.com/articles/s41467-026-76702-1
クリミア・コンゴ出血熱ウイルス核タンパク質を標的とする非中和性防御抗体の構造的およびメカニズム的知見 Structural and mechanistic insights into protective non-neutralizing antibodies targeting Crimean-Congo hemorrhagic fever virus nucleocapsid protein
Vanessa Moresco,Aura R. Garrison,Clarissa A. Edmundo,Collin J. Fitzpatrick,Elif Karaaslan,Scott P. Olschner,Keersten M. Ricks,Oluwadara T. Ogundare,Laliv Tadri,Brian D. Carey,Mohammad M. Sajadi,Éric Bergeron,Joseph W. Golden & Scott D. Pegan
Nature Communications Published:21 August 2026
DOI:https://doi.org/10.1038/s41467-026-76702-1 Early provide
Abstract
Crimean-Congo Hemorrhagic Fever Virus (CCHFV) is a tick-borne virus endemic to Africa, Asia, and expanding regions within Europe. With mortality rates approaching 40%, rising incidence, and no currently approved countermeasures, CCHFV is recognized as a priority public health threat. CCHFV nucleocapsid protein (NP) has long been a key target for diagnostics. Recently, NP-specific humoral responses have also been correlated with protection conferred by protective vaccines candidates. Additionally, the first non-neutralizing monoclonal antibody (mAb) 9D5 demonstrated protective efficacy against CCHFV challenge, underscoring NP as a viable antiviral target. Here, nine anti-NP mAb were utilized to identify four antigenic sites on NP as well as localize these sites to the head or stalk domains. These mAb also revealed variable levels of in vivo protection, independent from whether the epitope site is located in the head or stalk regions. Additionally, three X-ray crystallography structures were obtained that included CCHFV NP from strain Afg09-2990 in complex with the most potent mAb (9D5). This, along with additional structures of two unbound NPs, revealed structural elements critical for mAb-9D5 broad-spectrum protective characteristics. These findings provide a path towards the rapid identification of broadly protective anti-NP mAb countermeasures.
